Progression risk factors of ulcerative proctitis

References

• Dubois E, Moens A, Geelen R, et al. Long-term outcomes of patients with ulcerative proctitis: analysis from a large referral Centre cohort. United European Gastroenterol J. 2020;8(8):933–941.
   PubMed Web of Science ®Google Scholar
• Meucci G, Vecchi M, Astegiano M, et al. The natural history of ulcerative proctitis: a multicenter, retrospective study. Gruppo di studio per le malattie infiammatorie intestinali (GSMII). Am J Gastroenterol. 2000;95(2):469–473.
   PubMed Web of Science ®Google Scholar
• Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Digest Dis Sci. 1993;38(6):1137–1146.
   PubMed Web of Science ®Google Scholar
• Park SH, Kim YM, Yang SK, et al. Clinical features and natural history of ulcerative colitis in Korea. Inflamm Bowel Dis. 2007;13(3):278–283.
   PubMed Web of Science ®Google Scholar
• Gajendran M, Loganathan P, Jimenez G, et al. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019;65(12):100851.
   PubMed Web of Science ®Google Scholar
• Sahami S, Konté K, Buskens CJ, et al. Risk factors for proximal disease extension and colectomy in left-sided ulcerative colitis. United Eur Gastroenterol J. 2017;5(4):554–562.
   PubMed Web of Science ®Google Scholar
• Langholz E, Munkholm P, Davidsen M, et al. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol. 1996;31(3):260–266.
   PubMed Web of Science ®Google Scholar
• Nedelciuc O, Pintilie I, Dranga M, et al. Quality of life in patients with ulcerative colitis. Rev Med Chir Soc Med Nat Iasi. 2012;116(3):756–760.
   PubMedGoogle Scholar
• Kim B, Park SJ, Hong SP, et al. Proximal disease extension and related predicting factors in ulcerative proctitis. Scand J Gastroenterol. 2014;49(2):177–183.
   PubMed Web of Science ®Google Scholar
• Con D, De Cruz P. Mobile phone apps for inflammatory bowel disease Self-Management: a systematic assessment of content and tools. JMIR Mhealth Uhealth. 2016;4(1):e13.
   PubMed Web of Science ®Google Scholar
• Yin AL, Hachuel D, Pollak JP, et al. Digital health apps in the clinical care of inflammatory bowel disease: scoping review. J Med Internet Res. 2019;21(8):e14630.
   PubMed Web of Science ®Google Scholar
• ​​​​Eder P, Liebert A, Łodyga M, et al. The introduction of the IBD disk in Poland - a new tool for assessing disability in patients with inflammatory bowel disease. Prz Gastroenterol. 2020;15(1):55–59.
   PubMed Web of Science ®Google Scholar
• Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-Target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583.
   PubMed Web of Science ®Google Scholar
• Sakuraba A, Nemoto N, Hibi N, et al. Extent of disease affects the usefulness of fecal biomarkers in ulcerative colitis. BMC Gastroenterol. 2021;21(1):197.
   PubMed Web of Science ®Google Scholar
• Sonoyama H, Kawashima K, Ishihara S, et al. Capabilities of fecal calprotectin and blood biomarkers as surrogate endoscopic markers according to ulcerative colitis disease type. J Clin Biochem Nutr. 2019;64(3):265–270.
   PubMed Web of Science ®Google Scholar
• Lynch WD, Hsu R. Ulcerative colitis. [updated 2021 jun 18]. StatPearls [internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459282/
   Google Scholar
• Anzai H, Hata K, Kishikawa J, et al. Clinical pattern and progression of ulcerative proctitis in the Japanese population: a retrospective study of incidence and risk factors influencing progression. Colorectal Dis. 2016;18(3):O97–O102.
   PubMed Web of Science ®Google Scholar
• Huguet JM, Ferrer-Barceló L, Suárez P, et al. Endoscopic progression of ulcerative proctitis to proximal disease. Can we identify predictors of progression? Scand J Gastroenterol. 2018;53(10–11):1286–1290.
   PubMed Web of Science ®Google Scholar
• Satsangi J, Silverberg MS, Vermeire S, et al. The montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749–753.
   PubMed Web of Science ®Google Scholar
• Pica R, Paoluzi OA, Iacopini F, et al. Oral mesalazine (5-ASA) treatment may protect against proximal extension of mucosal inflammation in ulcerative proctitis. Inflamm Bowel Dis. 2004;10(6):731–736.
   PubMed Web of Science ®Google Scholar
• Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN study). Scand J Gastroenterol. 2009;44(4):431–440.
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014;89(11):1553–1563.
   PubMed Web of Science ®Google Scholar
• Walsh E, Chah YW, Chin SM, et al. Clinical predictors and natural history of disease extension in patients with ulcerative proctitis. Inflamm Bowel Dis. 2017;23(11):2035–2041.
   PubMed Web of Science ®Google Scholar
• Lie MR, Kanis SL, Hansen BE, et al. Drug therapies for ulcerative proctitis: systematic review and Meta-analysis. Inflamm Bowel Dis. 2014;20(11):2157–2178.
   PubMed Web of Science ®Google Scholar
• Roda G, Narula N, Pinotti R, et al. Systematic review with Meta-analysis: proximal disease extension in limited ulcerative colitis. Aliment Pharmacol Ther. 2017;45(12):1481–1492.
   PubMed Web of Science ®Google Scholar